Together, the partners aim to enable seamless access to integrated multi–species expertise, focusing on advanced preclinical drug development and automated histopathology services, streamlining preclinical research for both human and veterinary drug development.  

Diepenbeek and Izegem, Belgium, July 24th, 2025 – InnoSer, a preclinical contract research organization (CRO); Connected-Pathology, a CRO specialized in advanced digital histopathology; and Poulpharm, a CRO with expertise in microbiology and preclinical veterinary research, join forces to deliver integrated preclinical services tailored for both veterinary and human healthcare research.  

This strategic partnership is designed to enhance the preclinical capabilities of each partner, including advanced drug development and histopathology services. By aligning their complementary strengths, InnoSer and Poulpharm, through Connected-Pathology, will provide seamless preclinical support by integrating multi-species expertise, advanced digital histopathology, and streamlined workflows, accelerating research timelines.  

This strategic collaboration combines:   

• Connected-Pathology’s advanced histopathology and digital pathology services, expanding its scope into multi-species and translational studies 

• InnoSer’s translational research platforms and preclinical drug development capabilities 

• Poulpharm’s applied expertise in preclinical multi-species research and diagnostic services 

By working strategically together, the three partners aim to: 

• Provide seamless access to larger animal models and multi-species expertise, enabling faster, more informed and translational drug development 

• Deliver high-throughput histopathology services including IHC, IF, ISH, and AI-supported image and biomarker analysis across multiple study types  

• Provide end-to-end study support, from in vivo research to digital pathology and regulatory reporting 

“This partnership reflects our shared vision to deliver smarter, more connected research services,” said Maarten De Gussem, DVM, Manager and veterinarian at Poulpharm. Together, we are building a stronger, innovation-driven foundation for translational research.”  

“This partnership allows Connected-Pathology to extend its advanced digital histopathology solutions into broader preclinical applications across multiple species and diverse study types, significantly enhancing the depth and flexibility of our service offerings,” said Wim Tiest, Manager at Connected-Pathology. 

Kris Motmans, PhD, CEO of InnoSer, further adds, “The combined strengths of Poulpharm’s multi-species preclinical capabilities, InnoSer’s advanced drug development platform, and Connected-Pathology’s state-of-the-art histopathology services empower us to deliver seamless, integrated research solutions that accelerate drug development pipelines.” 

The collaboration ensures clients benefit from faster timelines, deeper insights, and seamlessly connected pathology and laboratory workflows — supporting the next generation of preclinical drug development.  

À propos d'InnoSer : 

Founded in 2012, InnoSer is an innovative and dynamic CRO supporting the pre-clinical development of drugs from its facilities in Belgium and the Netherlands. InnoSer supports its customers in the critical steps of their drug development journey with well-characterized in vitro and in vivo disease models in addition to general drug development services, allowing to uncover valuable insights into the mode of action, pharmacokinetics, safety, and efficacy of investigational compounds.    

www.innoserlaboratories.com  

About Connected-Pathology: 

Founded in 2021, Connected-Pathology allows CRO’s, biotechs, pharmaceutical companies, and academic organizations to focus on understanding the complexities of their research and less on the operations. We offer end-to-end histopathology assessments and a flexible workflow that allows our customers to outsource the service and support level needed. This workflow is built with cost-effective and reliable channels that are digitized, automated, and efficient, such as our TxConnect track-and-trace ordering system combined with AI assessment tools.   

www.connected-pathology.com  

About Poulpharm:  

Founded in 2006 and headquartered in Izegem, Belgium, Poulpharm is a trusted CRO providing high-quality research services in animal health. With a global presence in Europe and Asia, we operate under GCP and GLP standards across diagnostics, (pre-)clinical trials, and safety studies. Our diagnostic portfolio includes bacteriology, virology, molecular techniques, parasitology, haematology, histology, and bio-analytics, supporting accurate disease detection and treatment. Poulpharm conducts contract research on feed additives, vaccines, and veterinary drugs, using validated models for parasitic, bacterial, and viral diseases. Our end-to-end support helps clients move from concept to market with confidence. Poulpharm is your independent partner for innovation, compliance, and animal health excellence. 

www.poulpharm.com